summary: Some years ago interferon (IFN) beta was tested in people with a first episode suggestive of MS. It was proven to be effective in delaying the appearance of a second MS relapse. In the current study the authors have re-analysed the data from the former trial and have concluded that IFN beta was especially beneficial in delaying the second attack for those people whose first episode showed involvement of only one anatomical area. This finding reinforces the need for early disease modifying treatment after a first episode suggestive of MS, even when only mild anatomical involvement is observed.

authors: O'Connor P, Kinkel R, Kremenchutzky M

source: Mult Scler. 2009 Jun;15(6):728-34

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: